• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Smackover Lithium Successfully Completes Derisking of DLE Technology With Final Field-Test at South West Arkansas Project

    3/11/25 8:30:05 AM ET
    $A
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Major Chemicals
    Industrials
    Get the next $A alert in real time by email

    Field-Pilot DLE Facility Exceeds Key Performance Criteria to Confirm Engineering Design for South West Arkansas Project

    Large Volumes of DLE Product Sent to Third Party Vendors for Conversion to Battery-Quality Lithium Carbonate – These Samples Will Be Used in the Qualification Process With Potential Off-Take Partners

    LEWISVILLE, Ark., March 11, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, has achieved one of the last technical milestones in the development of the South West Arkansas ("SWA") project located in Lafayette and Columbia Counties, Arkansas. The JV, in partnership with Koch Technology Solutions ("KTS"), successfully completed the final Direct Lithium Extraction ("DLE") derisking step for the SWA project, a critical step toward commercialization. Over a three-month period, the JV and its partners operated an onsite DLE field-pilot plant, where it surpassed key performance criteria (more details provided below). Additionally, large-volume samples of the concentrated and purified DLE product have been sent to third-party vendors. These vendors will convert the DLE product into battery-quality lithium carbonate while also being assessed as potential equipment suppliers for the commercial project. The resulting samples will play a key role in the qualification process with prospective off-take partners.

    Highlights of this final derisking pilot include:

    • Lithium recovery far exceeded the design criteria. During sustained operation, the DLE field-pilot plant recovered over 99% of the lithium from brine sourced from the SWA project's International Paper Company ("IPC-1") well, far exceeding the 95% recovery used in the current design (average lithium content of the incoming brine was 427 mg/L);
    • Rejections for key contaminants were within acceptable tolerance of (i.e. just above or below) the design criteria;
    • The field-pilot plant processed over 2,385 barrels (100,170 gallons) of brine from the IPC-1 well;
    • Field-pilot plant completed over 497 DLE cycles;
    • These recent data from the field-pilot plant testing supplement the 28,367,185 gallons of brine processed, and the 11,206 cycles of DLE completed at Standard Lithium's Demonstration Plant in El Dorado, Arkansas, operating since 2020;
    • The heart of the plant is the same KTS Li-ProTM Lithium Selective Sorption (Li-Pro LSS) technology, as described in the Company's recent news release (28 October 2024);
    • The field-pilot plant has produced approximately 970 gallons (3,672 litres) of concentrated and purified lithium chloride solution (6% LiCl solution);
    • The 970 gallons of 6% LiCl solution is currently being sent off-site to three separate potential carbonate equipment vendors; and,
    • The three vendors are expected to produce, in total, approximately 27 kg of battery-quality lithium carbonate, anticipated in May 2025.

    Standard Lithium's President and COO, Dr. Andy Robinson commented "This field-pilot is the final step in derisking DLE technology for Smackover brines; we're now ready to commercialize this technology. For 5 years, Standard Lithium has been operating a large-scale Demonstration Plant in Arkansas, and we've processed over 28 million gallons of real, live Smackover brine. This large Demonstration Plant has been invaluable in developing, streamlining and optimising the flowsheet. The field-pilot was the final step to demonstrate that we can reliably process brine from our SWA project, extract lithium in real-time, and convert to a battery-quality lithium carbonate product. Smackover Lithium has now completed the necessary testing of the flowsheet, and can complete the FEED work and feasibility study."

    Standard Lithium operators checking performance of the DLE field pilot.  The larger blue and white enclosure houses the pre-treatment, filtration and DLE (LSS column) process steps.

    Figure 1 – Standard Lithium operators checking performance of the DLE field pilot. The larger blue and white enclosure houses the pre-treatment, filtration and DLE (LSS column) process steps.

    Standard Lithium operators monitoring performance of the filtration process step

    Figure 2 – Standard Lithium operators monitoring performance of the filtration process step.

    Qualified Person

    Marek Dworzanowski, EUR ING, CEng, HonFSAIMM, FIMMM, a qualified person as defined by National Instrument 43-101, and a Consulting Metallurgical Engineer who is independent of the Company, has reviewed and approved the relevant scientific and technical information in this news release.

    About Smackover Lithium

    Smackover Lithium is a joint venture between Standard Lithium and Equinor. Formed in May 2024, Smackover Lithium is developing two Direct Lithium Extraction ("DLE") Project Companies in southwest Arkansas and east Texas. Standard Lithium owns 55% interest and Equinor holds the remaining 45% interest in the two project Companies, with Standard Lithium retaining operatorship. For more information on the joint venture, please visit www.smackoverlithium.com.

    About Standard Lithium Ltd.

    Standard Lithium is a leading near-commercial lithium development company focused on the sustainable development of a portfolio of large, high-grade lithium-brine properties in the United States. The Company prioritizes projects characterized by the highest quality resources, robust infrastructure, skilled labor, and streamlined permitting. Standard Lithium aims to achieve sustainable, commercial-scale lithium production via the application of a scalable and fully integrated Direct Lithium Extraction ("DLE") and purification process. The Company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. In partnership with global energy leader Equinor, Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and actively exploring promising lithium brine prospects in East Texas. Additionally, the Company is advancing the Phase 1A project in partnership with LANXESS Corporation, a brownfield development project located in southern Arkansas. Standard Lithium also holds an interest in certain mineral leases in the Mojave Desert in San Bernardino County, California.

    Standard Lithium trades on both the TSX Venture Exchange and the NYSE American under the symbol "SLI"; and on the Frankfurt Stock Exchange under the symbol "S5L". Please visit the Company's website at www.standardlithium.com.

    About Equinor

    Equinor is an international energy company committed to long-term value creation in a low-carbon future. Equinor's portfolio of projects encompasses oil and gas, renewables and low-carbon solutions, with an ambition of becoming a net-zero energy company by 2050. Headquartered in Norway, Equinor is the leading operator on the Norwegian continental shelf and is present in around 30 countries worldwide. Our partnership with Standard Lithium to mature DLE projects builds on our broad US energy portfolio of oil and gas, offshore wind, low carbon solutions and battery storage projects.

    For more information on Equinor in the US, please visit: Equinor in the US - Equinor

    About Koch Technology Solutions (KTS)

    Koch Technology Solutions is the technology licensing business of Koch Engineered Solutions (KES). KTS creates value for its customers across a growing portfolio of technologies including direct lithium extraction, the polyester value chain, and 1,4-Butananediol plus its derivates. KTS combines its exclusive technologies, expertise, and capabilities with those of other KES companies to provide overall solutions to optimize customer's capital investments and existing manufacturing assets.

    Investor and Media Contacts:

    Chris Lang

    Standard Lithium Ltd.

    [email protected]

    Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This news release may contain certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward looking information" within the meaning of applicable Canadian securities laws. When used in this news release, the words "anticipate", "believe", "estimate", "expect", "target", "plan", "forecast", "may", "will", "schedule" and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to intended development timelines, future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, continued operation of the demonstration plant and the field-pilot DLE plant, outcomes of commercialization,  regulatory or government requirements or approvals, the reliability of third party information, continued production of lithium chloride solutions, consistent ongoing lithium recovery quantities, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements or information. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

    Figures accompanying this announcement are available at:

    https://www.globenewswire.com/NewsRoom/AttachmentNg/e0081645-6f2c-4fa8-9545-b3d522d892ef

    https://www.globenewswire.com/NewsRoom/AttachmentNg/8f0f751b-d576-4338-983a-a8b25f5c6d7e



    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $SLI

    CompanyDatePrice TargetRatingAnalyst
    Agilent Technologies Inc.
    $A
    1/20/2026$180.00Buy
    HSBC Securities
    Agilent Technologies Inc.
    $A
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    Agilent Technologies Inc.
    $A
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    Agilent Technologies Inc.
    $A
    12/9/2025$170.00Buy
    Goldman
    Agilent Technologies Inc.
    $A
    12/2/2025$270.00Overweight
    Morgan Stanley
    Agilent Technologies Inc.
    $A
    10/8/2025$165.00Buy
    Rothschild & Co Redburn
    Agilent Technologies Inc.
    $A
    10/8/2025$170.00Neutral → Buy
    UBS
    Standard Lithium Ltd.
    $SLI
    7/11/2025$2.75Outperform
    Raymond James
    More analyst ratings

    $A
    $SLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HSBC Securities initiated coverage on Agilent with a new price target

    HSBC Securities initiated coverage of Agilent with a rating of Buy and set a new price target of $180.00

    1/20/26 9:22:21 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Agilent from In-line to Outperform and set a new price target of $160.00

    1/5/26 8:23:48 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Barclays with a new price target

    Barclays upgraded Agilent from Equal Weight to Overweight and set a new price target of $165.00

    12/15/25 8:55:45 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Standard Lithium Ltd.

    SCHEDULE 13G - STANDARD LITHIUM LTD. (0001537137) (Subject)

    2/13/26 9:29:46 AM ET
    $SLI
    Major Chemicals
    Industrials

    SEC Form DEFA14A filed by Agilent Technologies Inc.

    DEFA14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    2/6/26 7:10:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEF 14A filed by Agilent Technologies Inc.

    DEF 14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    2/6/26 7:00:39 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

    Award honors leadership in sustainable laboratory practices and circular economy advancement Agilent Technologies Inc. (NYSE:A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent's inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent's trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and contributing to the circular use of scientific equipment. In 2025, Boehringer Ingelheim led all partners in responsible trade‑in activity, ensuri

    2/11/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

    Approval expands first-line PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. (NYSE:A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, enables pathologists to assess PD-L1 expression at the time of diagnosis, supporting informed treatm

    2/11/26 6:45:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by V.P., Corporate Controller Gonsalves Rodney

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    1/8/26 4:05:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dolsten Mikael sold $389,511 worth of shares (2,600 units at $149.81), decreasing direct ownership by 34% to 4,973 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    12/3/25 4:04:44 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President Zhang Jianmiao Mike covered exercise/tax liability with 208 shares, decreasing direct ownership by 2% to 11,639 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    12/1/25 4:36:53 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Names Adam S. Elinoff as Chief Financial Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027719923/en/Adam S. Elinoff, Chief Financial Officer, Agilent Technologies Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities. He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of

    10/27/25 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard Lithium Expands Leadership Team with Appointment of General Counsel

    VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI), a leading near-commercial lithium company, is announcing the appointment of Michael Lutgring as General Counsel, effective August 18, 2025. "We are excited to have Michael join our senior leadership team," said David Park, Chief Executive Officer and Director of Standard Lithium. "Michael's deep and wide-ranging experience will be critical as we strengthen our capabilities and bring further expertise in-house as we continue our growth and development as a public company." Mr. Lutgring brings over two decades of legal and strategic a

    8/18/25 8:30:00 AM ET
    $SLI
    Major Chemicals
    Industrials

    Standard Lithium Announces New VP Appointments to Expand and Strengthen Senior Management

    VANCOUVER, British Columbia, June 23, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI), a leading near-commercial lithium company, is pleased to announce the appointment of Daniel Rosen as Vice President of Strategy and Investor Relations, as well as Tim Sobel as Vice President of Health, Safety, Social and Environment ("HSSE"). "We are thrilled to welcome the additions of Daniel and Tim to our leadership team," said David Park, Chief Executive Officer and Director of Standard Lithium. "Dan's strategic insight and deep experience in investor relations and capital markets, as well as Tim's extensive history in ensuring that HSSE sta

    6/23/25 8:30:00 AM ET
    $SLI
    Major Chemicals
    Industrials

    $A
    $SLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Financials

    Live finance-specific insights

    View All

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25

    Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2026 after the stock market closes on Wednesday, Feb. 25. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full

    2/2/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Reports Fourth-Quarter Fiscal Year 2025 Financial Results

    Delivers solid results in Q4, initiates FY26 guidance Fourth-quarter fiscal year 2025 Revenue of $1.86 billion for the fourth quarter ended October 31, 2025, exceeding revenue guidance and representing growth of 9.4% reported and up 7.2% on a core(1) basis compared with the fourth quarter of 2024. GAAP net income of $434 million; earnings per share (EPS) of $1.53, up 25% from the fourth quarter of 2024. Non-GAAP(2) net income of $452 million; EPS of $1.59, up 9% from the fourth quarter of 2024. Full fiscal year 2025 Revenue of $6.95 billion for the fiscal year ended October 31, 2025, exceeding revenue guidance and representing growth of 6.7% on a reported basis and up 4.9% on a c

    11/24/25 4:10:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials